Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

You are Invited to Join LSN in Atlanta, Georgia, for RESI South, and Barcelona, Spain, for RESI Europe  

18 Jan

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN) is excited to announce two significant RESI partnering events in 2024. The first, RESI South, will be held in Atlanta, Georgia, on March 25, and the second, RESI Europe, will occur in Barcelona, Spain, on June 17th. These events mark a strategic expansion of LSN’s global partnering platform, providing a unique opportunity for its network of capital investors and licensing partners to engage with two dynamic innovation regions. The Super Early Bird rates are currently available for two upcoming RESIs. This is an excellent opportunity to register at a reduced cost before the deadline.

RESI South in Atlanta is particularly significant as it will showcase the burgeoning life science innovation ecosystem in the Southeastern United States. The Southeast LifeSci Investor Coalition, representing seven southern states (AL, FL, GA, NC, SC, TN, and VA), has united to spotlight the region’s wealth of early-stage drugs, devices, diagnostics, and digital health technologies. Thousands of startups are invigorating this innovation region. LSN estimates that hundreds of startups with technology transfer licenses are ready to explore the partnering opportunities that RESI South will bring.

The untapped potential of the Southeast is underscored by its receipt of 5.5 billion in NIH funding and 8.3 billion in academic research expenditures, making up 16% of all academic Bioscience R&D U.S. funding. LSN is thrilled to partner with the Southeast LifeSci Investor Coalition and is confident that its global partnering network will be able to explore this previously underserved market.

Following RESI South, LSN will host RESI Europe in Barcelona, Spain. The BioRegion of Catalonia has emerged as a leading force in the global life science landscape, boasting a thriving biotech and medtech startup ecosystem. The region’s strategic focus on business automation, connectivity, and the application of AI within diagnostics and treatments has attracted international life science players and positioned Catalonia as a hub for advanced therapeutics.

RESI Europe in Barcelona will leverage the BioRegion and showcase the broader Spanish life science ecosystems. RESI Europe also provides a great opportunity for global startups in Europe, North America, and APAC to get to Europe and meet the early-stage global players in the LSN European network. LSN expects a strong showing from its global capital investor and licensing partner network to attend this inaugural event.

LSN’s RESI Partnering Events in 2024 are set to provide a unique platform for global investors and startups to engage with two vibrant innovation regions. These events underscore LSN’s commitment to fostering cross-border partnerships and driving innovation across the global life science landscape. For more information about LSN and its initiatives, you can visit their official website at Life Science Nation.

Register-now-button-new

RESI-South-2024-11oo
RESI-SPAIN-1100

RESI JPM Recap: Record Investor Registrations and 3000 Connections Made 

18 Jan

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

Life Science Nation’s (LSN) biggest Redefining Early Stage Investments (RESI) event of the year, taking place during JP Morgan Healthcare week in San Francisco, was a huge success last week. With over 3000 meetings and connections made through RESI, it will be weeks before the true outcomes will be fully realized. With over 1100 attendees, spanning 35 countries and 5 continents, RESI hit a record high investor registrations, with 650 investors registered to attend, both in person and virtually. Of these investors, one third were investors who were new to RESI. RESI is the premier event for investors wanting to connect with early stage life science startups, and for every event, the LSN Investor Research team received outreach from new investors interested in joining our network and connecting with exciting new innovators.

In addition to meetings, RESI’s compelling content provides startups with opportunities to learn from investors, industry experts and their peers tips and techniques to make their fundraise successful. With panels such as the Family Offices, Big Pharma, Health System Partners and Cross Border Investors, companies were able to learn how different investor types partner in the early stages, and how to approach these investors most successfully. Other panels covered different sectors, such as Early Stage Therapeutics and Medical Devices, and even focused on areas gaining increasing traction such as Mental and Behavioral Health. These investor panels focused on current trends in the industry, and where they think it is headed in the near future. Panels hosted by industry experts focused on challenges companies can face and experts that can help them avoid issues that can delay them in their quest to bring their technologies to market. Cambridge Scientific hosted a session on procuring space in incubators and labs, as well as equipment, and how to navigate that to best advantage. Husch Blackwell hosted a session on navigating a fundraise with a complex technology, and how to explain your technology to best advantage when there is a complicated regulatory and intellectual property landscape.

The LSN network continues to expand with every RESI we organize, with new attendees and new content, and we are excited for 2024, which will include several new locations hosting our RESI conference. Check out our schedule for 2024, and join us for what is sure to be a full year of fantastic events.

RESI-South-2024-11oo

RESI JPM 2024 Program Guide

4 Jan

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN) releases the Program Guide for LSN’s RESI flagship event, RESI JPM, taking place next week, January 9 in person and on January 10-11 virtual! This hybrid conference will take place at the Marines’ Memorial Club & Hotel in San Francisco, and we are excited to release the digital version of the RESI Program Guide. Check out the various panelists, exhibitors, and workshops participating in this RESI. In addition, make sure to check out the Innovator’s Pitch Challenge, where over 50 companies will pitch to a panel of investor judges. Registration is still open for both in-person and virtual attendance. 

RESI-JPM-PG-Cover

Register-now-button-new

RESI-SF-2024-Banner-1100px new

Life Science Nation Announces the Redefining Early Stage Investments (RESI) for 2024 and You Are All Invited

4 Jan

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

Life Science Nation (LSN) will continue to drive innovation and breakthroughs throughout 2024. LSN’s Redefining Early Stage Investments (RESI) partnering events present a host of exciting opportunities for healthcare professionals, investors, and entrepreneurs to connect and collaborate in the healthcare arena. LSN events are aimed at fostering partnerships and driving the industry forward. LSN will feature five RESI partnering events that will shape the year ahead.  If you are a startup, the number one directive is to get out of your region and get into the global market and find capital investors and licensing partners that are a fit for your stage of development and product. The RESI partnering events allow you to get right into the middle of the North American, European, and Asia Pacific investor ecosystems.

Life Science Nation will kick off 2024 with RESI JPM, next week, January 9, in person and on January 10-11 virtual! This hybrid conference will take place at the Marines’ Memorial Club & Hotel in San Francisco. This conference is held during JP Morgan week and takes place in the major life science hub that is San Francisco and will, of course, have a great concentration of the hottest technologies being developed in the Bay Area and the plethora of VCs, Angels, Family Offices and Pharma/Medtech giants that help to fuel this amazing ecosystem.

LSN will follow RESI JPM, with RESI South, in partnership with a newly formed coalition, SELifeSci, consisting of life science associations representing Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. RESI South 2024 will occur via a hybrid format, with March 25th being in-person at the Whitley Hotel in Atlanta, Georgia, and the 26th and 27th with virtual partnering only.

Next up, RESI Europe Barcelona, a strategic collaboration with Biocat, headquartered in Barcelona, Catalonia, Spain, and Biotechgate, headquartered in Zurich, Switzerland. Biocat, a catalyzing organization dedicated to transforming the BioRegion of Catalonia into a premier life sciences and health innovation ecosystem in Europe, and Biotechgate, a pioneer in curating and marketing a global business development database tailored for the life science industry, join forces with LSN to bring the RESI global matching platform back to Europe. This conference will be held in person on June 17 at the Hilton Diagonal Mar Barcelona, followed by two days of virtual partnering, June 18-19.

In September, Life Science Nation is back in Boston – a hub of life science and healthcare innovation, at the Westin Copley, in person on September 25 and virtually, September 26-27. RESI Boston is in the hometown of LSN and is one of the premier partner events of the year.  Companies from all over the world come to RESI Boston to check out the global hub of life science and connect with the most dynamic healthcare ecosystem on the planet.  This event has been running for over a decade and is attended by the who’s who of the early-stage capital investment and licensing partners.

RESI Asia is planned for November, please stay tuned for an up-and-coming announcement on where this event will be taking place.

RESI 2024 Series

> Register Now

> Register Now

> Register Now

> Register Now

RESI-SF-2024-Banner-1100px new

Corval Returns to RESI

4 Jan
Susan-NemetzSusan Nemetz
 Interview with Susan Nemetz, CEO at Corval

By Caitlin Dolegowski, Marketing Manager, LSN

 CaitiCaitlin Dolegowski

Caiti Dolegowski (CD): We are pleased to have Corval back as a Redefining Early Stage Investment (RESI) sponsor for LSN’s upcoming RESI JPM conference in San Francisco! For those who may not have connected with you at RESI Boston in September, introduce us to Corval. 

Susan Nemetz (SN): Corval® is a strategic planning platform that enables teams to quickly create a tailored multi-year commercialization map with a companion budget and resource plan. We specifically designed Corval for biopharma companies (or their consultants) that need the highest quality expert thinking but don’t yet have the internal capabilities to manage early commercialization priorities.

Corval is pre-populated with 75,000 data points informed by industry benchmarks across different biopharma companies and therapeutic areas. Biopharma leaders just need to guide the platform with their unique clinical and regulatory milestones, asset assumptions, and company information then let Corval do the heavy lifting. The Corval platform quickly builds a 3-5 year strategic commercialization map, budget, and hiring plan with multiple executive views. The integrated logic allows them to quickly update the full plan when timelines and data change as they always do.

CD: Susan, you are the Founder & CEO of Corval, tell us more about yourself and how Corval came to be. 

SN: I have been in the biopharma industry my entire career across different roles and company types. I have seen the amazing contributions our industry makes in science and for patients and I have seen the inefficiency, some of which can be addressed through technology.

In addition to founding and leading Corval, an innovative software company, I am the CEO and Founder of The NemetzGroup, a successful, strategic commercialization consultancy. The NemetzGroup has been instrumental in supporting the evolution of over 200 biopharma companies from startup to publicly traded and the development of numerous assets from targets to approved, life-saving treatments. With more than 35 years of corporate strategy, commercial, medical affairs, business development, and operational experience, C-suite leadership teams rely on our thought partnership and mentoring to achieve goals across all stages of drug development.

Prior to launching The NemetzGroup in 2003, I held various corporate roles including as Vice President, Global Commercial Strategy, and then Vice President of International Commercial Operations at Millennium Pharmaceuticals. Previously, I was fortunate to progress through multiple commercial leadership roles at DuPont Pharmaceuticals that culminated in a role as Executive Vice President of the cardiovascular and imaging franchise. I also serve as an advisor of Life Science Cares, a collective effort of the life science industry to eliminate the impact of poverty on Boston neighborhoods and I am on the Board of Directors of Good Shepherd Community Care. Good Shepherd is dedicated to delivery of the highest quality of palliative and hospice care, support, and education for those experiencing serious illness or loss.

CD: What can RESI JPM attendees learn from you and who are you looking to connect with at RESI? 

SN: We are interested in speaking to anyone who has a vision for their asset and needs to make sure all the steps and resources required are accounted for so their drug will get to the patients who need it. Specifically, pre-commercial companies at about P2 who need to understand what it takes to commercialize in either a go-it-alone or partnering scenario. Often these companies are also looking for funding and need to tell the story regarding use of proceeds to commercialize their asset. In summary, we are looking to speak to companies who are building plans that involve one pre-commercial asset or portfolio of assets and may also involve modeling or comparing different scenarios to inform strategic decisions.

Since we were last at RESI, we have introduced an enterprise offering of Corval which means the platform can also transform how service providers, VC/PE firms support their clients. Our platform supports firms to:

  • Create a market advantage by engaging prospects with a dynamic, real-time strategic planning tool 
  • Provide an innovative, collaborative, and flexible client/consultant interface for planning, support, and transparency across all functions 
  • Analyze and manage their portfolio across all accounts to maximize service offerings to guide clients and support relevant business development

CD: Who among Corval’s staff will be attending RESI? 

SN: Our Business Development Representative Nigel Cawthon and Head of Engineering & Technology, Paul Sohal, will be attending the RESI JPM conference. They attended in September and had a wonderful time and really enjoyed the connections they made. They are thrilled to be back.

CD: What worked well for Corval at RESI September and what connections were made? 

SN: With the pre-conference app, RESI made it effortless for us to connect with likeminded individuals and anticipate meaningful conversations before we even entered the building. The entire event was incredibly well-organized with engaging breakout sessions on industry trends and thought leadership—as well as funding opportunities and grants for early-stage companies. Both during the conference and after in follow-up conversations, RESI was a tremendous opportunity to showcase and illustrate Corval’s technology and innovation in biopharma commercialization. 

CD: RESI hosts early-stage startups, what is the optimal timing for a biopharma company to prepare for the commercialization process? 

SN: Begin planning early, but stage-gate your implementation. Most failed launches are becausecritical steps were not completed early enough, or they missed some entirely. 

Early-stage biopharma often ignores the need or kicks the can down the road in later P3 because they are only focused on the science. But studies have proven that the companies that DO engage in early strategic planning are much more likely to reach their financial goals and serve the patients’needs that are a focus of their science. I cannot stress enough the importance of planning asearly as possible (typically around Phase 2) so commercialization thinking can inform in allaspects of clinical development resulting in a strong differentiated product profile that is the foundation of success in the market at launch and over the product life cycle. This is why we all do what we do in this industry. Use Corval, and you will save time, money, energy, and, just maybe, your sanity! 

RESI-SF-2024-Banner-1100

Interview with Dennis Ford, Founder of Life Science Nation, Regarding the RESI JPM Partnering Conference January 9-11, 2024.

28 Dec
GRGEGreg Mannix Interview with Dennis Ford

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

 DF-News-09142022Dennis Ford

Gregory Mannix: Please Explain why Life Science Nation’s Redefining Early Stage Investments (RESI) conferences are a good strategy for a startup seeking capital investment and licensing partners. 

Dennis Ford: It is very hard navigating all the partnering events and conferences if you are a startup with a limited budget, and trying to figure out which events will be best and most fruitful for you and your firm. 

 The first thing is getting in context; if you are raising a seed, Series A or Series B round, it can take 9-18 months to complete a round. Secondly, it is a numbers game. You must increase your visibility to as many potential players as possible, and it is not enough to go to a few events a year. You must be committed to being out in the marketplace, kissing many frogs, hearing many nos, and not being deterred. Third, this is not a part-time undertaking. It takes dedication to do a global fundraising campaign. It is a journey; you will have ups and downs along the way and must persevere.  

GM: What is your fundamental advice to startup CEOs? 

DF: My advice to startup CEOs is: every time you stick out your hand, you will be giving up as much as 20% of your company, so make sure you do the math and know how much cash you need for the next 24-36 months so that you have cash and runway to make your milestones and get your data for your next inflection point before the next round.   

GM: What is the distinct differentiator for a RESI Partnering Event? 

DF: RESI is unique because it has been a dedicated partnering event for over a decade, and while other events may have 10-15% investors in attendance, 50% of RESI’s attendees are investors. This bodes well for booking meetings with investors who fit your product and stage of development. Follow the money! 

 RESI is cross-border; we have three events in the U.S., one in Europe, and one in Asia, and it is also cross-silo, meaning that the buy-side attendees are seeking early-stage drugs, devices, diagnostics, and digital health (the 4Ds) startups for their portfolios. A startup can follow the RESI events every few months worldwide and use RESI to execute their global roadshow.  

GM: Who attends a RESI event? 

DF: The audience is well defined. As stated, the attendees are split 50/50 between sell-side startups across the 4Ds and ten categories of buy-side investors and licensing partners. This makes RESI partnering events incredibly interactive, and deals get done. LSN estimates that we have helped over 400 startups raise over $5B. The startup-to-investor ratio has been the same for the last ten years. The investors range from angels and family offices to early-stage VC and PE, Big Pharma and MedTech strategics, and corporate and government funders. 

GM: Startups are frustrated with the extravagant pricing models to attend events today. What has LSN done to help with this pricing pain point? 

DF: LSN introduced a flexible pricing model during COVID-19 that coincided with our virtual conferences that have morphed into present-day pricing. The challenge is finding price points that fit a startup company’s ever-changing stage of development.   For example, if you are a new startup, you can buy an audience access pass for $595. Although you will not have access to the partnering system, you can experience all the investor panels and workshops firsthand to see how other startup CEOs leverage RESI in their fundraising campaign.  They can attend pitch challenges to see how other start-up CEOs pitch to investors and subsequently observe investor reactions and questions. Attending RESI and learning through observation is invaluable for a newcomer.  

Presently, RESI is a three-day event with one face-to-face and two virtual days, so we adjusted the pricing so a startup can purchase a one-day, in person event with partnering for $1,795. Alternatively, the standard three-day package costs $2,295, which allows flexibility and is very competitive with the extravagant pricing that is out in the event arena today. Lastly, for a company that wants to participate in partnering, but cannot physically attend the conference, they can register for a virtual-only pass that costs $1,195, allowing them to connect with investors via videoconferencing. 

RESI-SF-2024-Banner-1100px new

Companies To Watch In 2024

28 Dec

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

DF-News-09142022

For the past ten years, Life Science Nation (LSN) has built a global partnering platform that matches scientist-entrepreneurs and fundraising CEOs with capital, licensing, and product collaboration partners. In that time, LSN has learned so much about what makes a compelling fit for our buy-side partners. I have had discussions with hundreds of investors. I always want to understand how their investment theme of seeking early-stage technology assets is balanced with the risk of going early. Unsurprisingly, it’s complicated, but it typically revolves around focusing on key attributes of the company, the science, the management team, key milestones already achieved, and the all-important data that supports that the technology is heading in the right direction. 

Similarly, I have developed my own set of attributes that I personally look for when I meet the companies that are referred to me through LSN’s relationship with regional tech hubs, incubators, and accelerators or national government and state life science agencies. These are what I look for: 

  • The Founding Scientist – Is there a scientist with a long lineage with the key science and the technology assets inside the company? A lot of the “new” technologies are actually the latest iteration of technologies that have been worked on for decades. When the scientist that is associated with that technology is still involved either as CTO, advisory or board compacity, that helps de-risk the opportunity. Having the world-renowned expert onboard and that thread of historical continuity provides not only perspective, but credence to the validation and the translating of the technology. Even if the assets are not that old, a thorough comprehension of the history, context, and potential to show future partners that the technology is in the hands of leadership with an appropriate understanding and appreciation of what it is capable of. 
  • The CEO – There are a few categories of CEO that I see in many of these startups. Experience matters and which side of the house the startup CEO has been on in the past matters and will affect how the company addresses the challenges that will surface along the startup journey. Personally, I have an affinity for the CEOs who were mid-level executives in big drug or device companies, and who were responsible for managing and getting successful products out the door in the past. It is even better when one or more of those products was a blockbuster. This is the type of CEO that has been-there-done-that in a corporate play and now wants to take all that knowledge, expertise, and leverage it in a new startup. I then ask myself, “Can this CEO listen? Is he/she coachable with an ability to learn quickly and discern, accept, and apply sound feedback?” 
  • Management Team – I like a diverse management team with similar experience as described above that augments and complements the CEO. A CEO should not surround themselves with a team that closely resembles their own strength and skillset. A savvy CEO will build a team with relevant experience and together possess expertise in how the game is played. They understand from past corporate experience when to hold them, when to fold them, and when to pivot. A diverse professional team that has seen success in the past and now wants to take their startup to the big leagues will generate traction and get their exit. 
  • Milestones and Data – Show a cogent well-thought-out plan based on hitting realistic achievable milestones that will produce compelling, validating data to show that the product is on the right path and going in the right direction. CEOs and their teams gain credibility when they present this aspect honestly and correctly, and when they are not coordinated, they lose credibility, and thus a chance for partnerships. Having realistic milestones that will produce compelling validating data is crucial to partnering. 
  • Entrepreneurial Agency – I have been talking about entrepreneurial agency for a while now. It’s hard to describe, but you know it when you see it. It’s the vibe you get, the confidence that is exuded, the passion, the professionalism, the unbridled desire, and determination. Entrepreneurial agency gives a company mojo which, in turn, creates positive propulsion forward. I mentioned that I like to see seasoned CEOs with experience in large enterprises that are now leading startups and taking their shot. However, there remain many seats at the table for the young, dynamic CEO that has followed their passion and their love for finding a scientific solution for an unmet medical need and wants to impact the healthcare arena. There are plenty of both types of CEOs in the early-stage arena, and that is driving this golden age of life science that we are all living in.   

Drum Roll Please: My companies to Watch in 2024, 

Thrive-Bioscience

Cell and tissue culture has been performed the same way for 60 years, even though this process is key for almost all segments of life science research and delivery of medicine. Thrive Bioscience’s automation of cell and tissue culture is doing for cell biology what sequencing did for genomics — providing extensive amounts of previously unavailable data and images that are comparable and actionable. Thrive has booked $13 million of orders in the last nine months, selling its family of instruments and software primarily to pharma/biotech, CROs, and medical labs. The Thrive platform vastly improves imaging, analytics, and automation capabilities that significantly improves research, medical and bioprocessing fields that create, develop, and deliver new drugs, devices, and diagnostics products to the marketplace. 

indiebio (2)FlexPerc has revolutionized the tumor treatment process with AI and robotic technology, which will be a game changer not only for the patients but will become the standard of care and a first-line treatment for lung cancer tumors needing ablation, biopsies or drug delivery.  FlexPerc’s minimally invasive platform comprises of an AI-based treatment planning software, a flexible ablation device, and an interventional robotic system. This product heralds the dawning of a new age of precision, autonomous cancer intervention tools that will drastically change the surgical landscape.  

Ternalys TherapeuticsTernalys‘ novel SAGUARO platform provides a simple yet elegant way to simultaneously deliver multiple microRNAs on a biologically flexible scaffold (a “microRNA construct”), replenishing cancer cells with microRNAs that are present in normal cells and thereby reversing the defensive epigenetic changes. In our work to date, we have demonstrated the ability to synergistically enhance existing therapies and, by doing so, potentially alter the outcomes for many intractable cancers. Ternalys’ lead compound, TT-003, is focused on the difficult and highly underserved area of glioblastoma. We believe that TT-003 has the potential to progress rapidly into clinical development and provide meaningful clinical results because of its unique capability as “miRNA replacement therapy” for multiple miRNAs. 

Cari Health CARI Health is developing a wearable remote medication monitor that enables personalized dosing and adherence monitoring to increase  medication adherence. The platform monitors medications in the interstitial fluid in real time via a novel, patent pending electrochemical sensor. The sensor can detect many medications, but CARI will prove the platform capability first with methadone, a medication used to treat opioid addiction. 

Cardathea-IncCardathea’s non-invasive, electric field imaging system helps cardiologists more quickly and accurately implant cardiac pacemaker “leads,” saving procedure time and improving clinical outcomes.  In the U.S. alone, physicians implant ~16,000 pacemakers and ~12,500 ICDs each month.  By enabling the broad adoption of cardiac conduction system pacing, our system would enable significant market share gains by an acquiring cardiac pacing system company.  The pacemaker system market is $4.2B WW.  

BrainStorm TherapeuticsBST is a biotech startup dedicated to addressing the pressing global brain disease crisis. At BST, we are developing an innovative AI-powered human brain organoid platform to develop groundbreaking therapies that halt, prevent, or reverse synaptic network dysfunction and neurodegeneration. The challenges of Central Nervous System (CNS) drug discovery are formidable, marked by an incomplete understanding of the diverse nature of brain disease biology and the absence of reliable animal models that accurately predict human efficacy. To overcome these challenges, we are developing a CNS drug discovery engine by applying a precision medicine approach focused on human genetics, human brain organoids, clinically translatable screening endpoints, advanced data analytics, and network medicine. 

PrapelaPrapela is an award winning pediatric medical device startup working with clinicians to help improve the treatment of newborns with specific medical conditions – especially those where breathing and heart rate are a concern. Over a decade ago, clinicians and scientists developed a unique vibrating pad to help newborns breathe, relax and sleep. At Prapela, we’re working to make this breakthrough available to help infants and their caregivers everywhere. Our extremely gentle vibration moves randomly within a very narrow range of up & down movement and speed. It’s based on a field of science called Stochastic Resonance which explains that biological processes (like breathing and heart rate) can be improved with random stimulation. For more information, visit prapela.com 

BioMark OncologyBiomark Ocology is a translationally enabled cancer therapeutics company. We are developing potential first-in-class medicines for solid tumor indications with mechanisms of action and target validation focused on whole systems biology. We believe that this approach, akin to the discovery of immune checkpoint inhibition targets, will enable the next step-function change in solid tumor efficacy and move previously overlooked but valuable targets forward. To derisk these programs, we are developing a multi-omics predictive biomarker platform measuring >1000 plasma biomarkers. We use machine learning cluster analysis to find systemic differences in responders and nonresponders in a heterogenous patient population. This will enable host-based predictive biomarkers to complement tumor-based strategies to select the right cancer drug for the right patient. 

Convergence MedicalConvergence Medical Pty is a Brisbane based medical device company, focused on the advancing arthroscopy with design and development of the world’s first arthroscopic robot (the V01 – Arthroscopic Surgical Robot). We exist to address the significant problems in arthroscopic surgery, improving the lives of the 50 million patients treated every year and the 30 thousand surgeons who perform these operations. The V01 is developed to change practice by providing ridged stability and robotic precision, power by an immersive and intuitive interface making operations simpler and more efficient. These innovations are designed to help the 70% of surgeons who perform these procedures and regularly experience significant muscular skeletal pain, the 30% of surgeons forced to retire early, the third of surgeons that state they don’t feel confident with their abilities and the 40% of patients which have observable damage during an operation. 

RevBioIt all started in nature with bio-inspiration from an amazing marine animal known as the Sandcastle Worm. Headquartered in Lowell, the company includes an extensive team of scientists, engineers, and clinicians who have reverse engineered a mineral-organic compound into a patented bioadhesive with an extensive platform of bone repair applications. A MassChallenge start-up accelerator alum, RevBio has won over 10 grants, received multiple patents, and is conducting its first-in-human clinical trial on its biomimetic bone adhesive. 

← Older Entries
Newer Entries →